These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 7562123

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R, Pagano D, Mazzotta G, Rosen SD, Fattore G, De Caterina R, Gensini G.
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W, Pierre K, Massel D.
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ.
    Ann Intern Med; 1994 May 15; 120(10):876-81; discussion 882-5. PubMed ID: 8154647
    [Abstract] [Full Text] [Related]

  • 10. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
    Heyland DK, Gafni A, Levine MA.
    J Clin Epidemiol; 2000 Sep 15; 53(9):888-94. PubMed ID: 11004415
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
    Fryback DG, Chinnis JO, Ulvila JW.
    Int J Technol Assess Health Care; 2001 Sep 15; 17(1):83-97. PubMed ID: 11329847
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
    Hiatt MD.
    Cardiology; 1999 Sep 15; 91(4):243-9. PubMed ID: 10545680
    [Abstract] [Full Text] [Related]

  • 18. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM, Stump D, Topol EJ, Mark DB.
    Am Heart J; 1999 May 15; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract] [Full Text] [Related]

  • 19. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
    White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ.
    Circulation; 1996 Oct 15; 94(8):1826-33. PubMed ID: 8873656
    [Abstract] [Full Text] [Related]

  • 20. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM.
    JAMA; 1996 Mar 13; 275(10):777-82. PubMed ID: 8598594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.